H.C. Wainwright initiated coverage on Evommune (NYSE: EVMN) with a Buy rating and a $35.00 price target.
The firm said recent share price weakness had created a favorable risk-reward profile ahead of key 2026 clinical readouts, particularly as competition within the MRGPRX2 space had narrowed. H.C. Wainwright described Evommune as offering exposure to large, underserved inflammatory and immunology markets, with improving strategic optionality.
The analyst highlighted early human proof-of-concept data in chronic inducible urticaria, which it said supported read-through to chronic spontaneous urticaria. A clean safety profile across early studies was also cited as an important differentiator, especially given recent toxicity-related setbacks in other oral MRGPRX2 programs.
Evommune was founded by the team that previously built Dermira, which was sold to Eli Lilly for $1.1 billion, and advanced lebrikizumab and Qbrexza into commercial products. The company is currently advancing two clinical-stage assets: EVO-756, an oral MRGPRX2 inhibitor for CSU and atopic dermatitis, and EVO-301, an IL-18 inhibitor for atopic dermatitis and ulcerative colitis. H.C. Wainwright said positive 2026 data could drive both valuation upside and strategic interest.
